
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc has demonstrated significant revenue growth, with total revenue increasing by 84.7% year-over-year, largely driven by a remarkable 117.2% increase in Genomics revenue, which reached $252.9 million. The company is also experiencing a favorable shift in its product mix, as evidenced by expected higher average selling prices (ASPs) from its xF liquid biopsy assay and the xT CDx test, which should enhance margins and profitability. Furthermore, the anticipated signing of additional pharmaceutical contracts and the potential increase in oncology testing volumes following reimbursement for its xM test present a robust opportunity for sustained financial improvement.
Bears say
The financial analysis of Tempus AI Inc reveals underlying concerns regarding the company's profitability and growth trajectory, highlighted by a decline in gross margins from 76.8% in Q3 2024 to 69.7% in Q3 2025. Additionally, the company continues to face significant risks, including competition, regulatory hurdles, and potential difficulties in acquiring and retaining partnerships, all of which pose threats to projected sales growth. Furthermore, with ongoing substantial losses since inception, a high debt burden of $518.8 million, and decreased operating cash flow, Tempus AI's ability to achieve sustainable profitability appears increasingly tenuous.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares